Wednesday , May 27 2020
Home / Real-World Economics Review / Why do economists have such a hard time imagining open source biomedical research?

Why do economists have such a hard time imagining open source biomedical research?

Summary:
From Dean Baker It seems more than a bit bizarre, but in a discussion of alternative to patents for financing the development of new drugs and vaccines, publicly funded open-source research is not mentioned.  This is peculiar since so much of the research into treatments and vaccines for the coronavirus are in effect being open-sourced, with researchers posting results as soon as they are available. Advance, open-sourced funding would mean that any new drugs or vaccines that are developed could be sold as cheap generics from the first day they are available. It is also bizarre that economists have such a hard time envisioning open source research, since all of our research is essentially open source. Economists are paid by universities and think tanks. Extraordinary work can qualify

Topics:
Dean Baker considers the following as important:

This could be interesting, too:

V. Ramanan writes Jeremy Corbyn On His And Tony Benn’s Positions On The EU And Brexit

V. Ramanan writes Neochartalists’ Rhetoric Against Raising Taxes

Lars Syll writes Economic models and reality

V. Ramanan writes Joan Robinson On Public Sector Deficits And Debt

from Dean Baker

It seems more than a bit bizarre, but in a discussion of alternative to patents for financing the development of new drugs and vaccines, publicly funded open-source research is not mentioned.  This is peculiar since so much of the research into treatments and vaccines for the coronavirus are in effect being open-sourced, with researchers posting results as soon as they are available. Advance, open-sourced funding would mean that any new drugs or vaccines that are developed could be sold as cheap generics from the first day they are available.

It is also bizarre that economists have such a hard time envisioning open source research, since all of our research is essentially open source. Economists are paid by universities and think tanks. Extraordinary work can qualify for a Nobel Prize, which is a big chunk of money, but the vast majority of economists get the bulk of their income from ongoing funding streams, where they are expected to produce research that will be widely available.

Perhaps economists believe that this route has not been effective in supporting good research in economics. This could explain their reluctance to envision open source research in biomedical innovation and elsewhere.

Dean Baker
Dean Baker is a macroeconomist and codirector of the Center for Economic and Policy Research in Washington, DC. He previously worked as a senior economist at the Economic Policy Institute and an assistant professor at Bucknell University. He is a regular Truthout columnist and a member of Truthout's Board of Advisers.

Leave a Reply

Your email address will not be published. Required fields are marked *